Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164342
Title: | Analysis of HIV-1 Fusion Peptide inhibition by synthetic peptides from E1 protein of GB virus C |
Author: | Sánchez Martín, Ma. Jesús Hristova, Kalina Pujol Cubells, Montserrat Gómara Elena, María José Haro, Isabel Alsina Esteller, Ma. Asunción Busquets i Viñas, Ma. Antonia |
Keywords: | VIH (Virus) Síntesi de pèptids Hepatitis G Liposomes Microscòpia confocal HIV (Viruses) Peptide synthesis Hepatitis G Liposomes Confocal microscopy |
Issue Date: | 1-Aug-2011 |
Publisher: | Elsevier |
Abstract: | The aim of this study was to identify proteins that could inhibit the activity of the peptide sequence representing the N-terminal of the surface protein gp41 of HIV, corresponding to the fusion peptide of the virus (HIV-1 FP). To do this we synthesized and studied 58 peptides corresponding to the envelope protein E1 of the hepatitis G virus (GBV-C). Five of the E1 synthetic peptides: NCCAPEDIGFCLEGGCLV (P7), APEDIGFCLEGGCLVALG (P8), FCLEGGCL VALGCTICTD (P10), QAGLAVRPGKSAAQLVGE (P18) and AQLVGELGSLYGPLSVSA (P22) were capable of inhibiting the leakage of vesicular contents caused by HIV-1 FP. A series of experiments were carried out to determine how these E1 peptides interact with HIV-1 FP. Our studies analyzed the interactions with and without the presence of lipid membranes. Isothermal titration calorimetry revealed that the binding of P7, P18 and P22 peptides to HIV-1 FP is strongly endothermic, and that binding is entropy-driven. Gibbs energy for the process indicates a spontaneous binding between E1 peptides and HIV-1 FP. Moreover, confocal microscopy of Giant Unilamellar Vesicles revealed that the disruption of the lipid bilayer by HIV-1 FP alone was inhibited by the presence of any of the five selected peptides. Our results highlight that these E1 synthetic peptides could be involved in preventing the entry of HIV-1 by binding to the HIV-1 FP. Therefore, the continued study into the interaction between GBV-C peptides and HIV-1 FP could lead to the development of new therapeutic agents for the treatment of AIDS. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.jcis.2011.04.053 |
It is part of: | Journal of Colloid and Interface Science, 2011, vol. 360, num. 1, p. 124-131 |
URI: | http://hdl.handle.net/2445/164342 |
Related resource: | https://doi.org/10.1016/j.jcis.2011.04.053 |
ISSN: | 0021-9797 |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
602037.pdf | 849.14 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.